However, neoadjuvant ALK-TKI therapy for patients with locally advanced unresectable N3-stage NSCLC harboring ALK rearrangement has only been reported in isolated cases (Zhai et al., 2023). Here, ALK is linked to non-small cell lung carcinoma.